Amirfarbod Yazdanyar, MD
Retina Specialist · New Hartford, NYNPI 1811332083
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,962 of the $12,149 with a category attached, or 73.8%. 11 manufacturers reported payments, led by Regeneron at 59.4% of the total. 2025 is the largest year on record at $7,428, more than ten times the $222 reported in 2019.
Across 30 payments — averaging $404.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$7K
- Astellas Pharma US Inc$3K
- Ocular Therapeutix, Inc.$1K
- Regeneron Healthcare Solutions, Inc.$230
- Genentech USA, Inc.$186
- Alcon Research LLC$182
- plus $505 from 5 others
Across 1 payment — averaging $1196.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$1K
What the payments were for
- Consulting fees$8,96274%
- Travel & lodging$1,0979%
- Food & beverage$2,09017%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 10 | $7,219 |
| Astellas Pharma US Inc | 3 | $2,649 |
| Ocular Therapeutix, Inc. | 7 | $1,179 |
| Regeneron Healthcare Solutions, Inc. | 2 | $230 |
| Genentech USA, Inc. | 2 | $186 |
| Alcon Research LLC | 1 | $182 |
| Amgen | 1 | $125 |
| Dutch Ophthalmic, USA | 1 | $105 |
| Glaukos Corporation | 1 | $99 |
| Bausch & Lomb Americas Inc. | 1 | $89 |
| Genentech, Inc. | 1 | $86 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA HD$6,922
- Izervay$2,649
- DEXTENZA$137
- EYLEA$135
- Lucentis$127
- KRYSTEXXA$125
- EVA, combined machine$105
- TISSUEBLUE$105
How this compares
$12,149 in reported general payments places this provider in the 80th percentile of 99 retina specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 152 | $8,090 |
| Ketorolac Tromethamine | 156 | $3,867 |
| Bromfenac Sodium | 11 | $1,466 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 15 | $1,332 |
| Ofloxacin | 82 | $1,034 |
| Brimonidine Tartrate | 14 | $195 |
| Latanoprost | 13 | $129 |
| Dorzolamide Hcl | 18 | $88 |
| Timolol Maleate | 19 | $76 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in New Hartford
- Paul HahnNanuet$238K
- Deepika MalikWoodbury$221K
- Szilard KissNew York$195K
- Ferhina AliValhalla$176K
- Donald D'amicoNew York$109K
- Matthew WitmerRochester$62K
- Avnish DeobhaktaBrooklyn$46K
- Edward HallRochester$38K
- Philip NilesWilliamsville$30K
- Mark BreazzanoLiverpool$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.